Companies Owned by Johnson & Johnson (2026)

What companies and brands does Johnson & Johnson actually own in 2026?

The honest answer starts with a correction most lists get wrong: Johnson & Johnson no longer owns the household consumer brands people most associate with the name. In 2023 the company completed the separation of its consumer-health division into an independent company called Kenvue. Tylenol, Neutrogena, Aveeno, Band-Aid, Listerine, and the Johnson's baby line all went with it. So if you are cataloguing what J&J owns today, those belong on a different page.

What remains is a focused healthcare company built on two operating segments. The first is Johnson & Johnson Innovative Medicine, the pharmaceutical arm that for decades carried the Janssen name and was rebranded under the J&J corporate identity from September 2023 onward. The second is Johnson & Johnson MedTech, the medical-device arm spanning surgery, orthopaedics, cardiovascular care, and vision. Between them they own the drug and device brands that now define the company.

Every one of those brands sits inside a corporate structure made of subsidiaries, and a large share of those subsidiaries are organized in Delaware. That is the thread this page pulls on: the same legal vehicle a $400-billion multinational uses to hold its US operations is available, in single-entity form, to a founder forming their first company. The mechanics scale down cleanly to a single Delaware LLC.

Is Johnson & Johnson a Delaware company or a New Jersey company?

It is a New Jersey company at the top. The publicly traded parent, Johnson & Johnson, has been incorporated in New Jersey since its early history and is headquartered in New Brunswick, New Jersey. That is an important nuance, because plenty of writeups assume every corporate giant is a Delaware corporation. J&J is one of the well-known exceptions where the listed parent stayed in its home state.

The Delaware connection lives one level down. Large US groups commonly organize their operating companies, holding companies, and acquisition vehicles as Delaware entities even when the parent is incorporated elsewhere. Delaware's settled corporate case law and its specialized business court make it the default home for the subsidiaries that actually sign contracts, hold intellectual property, and absorb acquired businesses. The parent's state of incorporation and the subsidiaries' states of incorporation are simply two different questions.

For a founder, the takeaway is reassuring: you do not need to match J&J's exact setup to benefit from Delaware. You are choosing the same jurisdiction those subsidiaries use, just with one entity instead of hundreds. The Delaware LLC formation process gives you that footing directly.

What does J&J Innovative Medicine (formerly Janssen) own?

Innovative Medicine is J&J's prescription-drug business, and its portfolio is a mix of in-house discovery and large acquisitions. The brands below are genuinely owned and marketed by the segment — these are drug names, not separate companies, but they represent the assets that drive this side of the business.

• Stelara and Tremfya — immunology treatments used in conditions such as plaque psoriasis.
• Darzalex and Imbruvica — blood-cancer therapies in the oncology portfolio.
• Erleada — an androgen-receptor inhibitor used in prostate cancer.
• Xarelto — an anticoagulant J&J markets in the United States.
• Opsumit, Uptravi, and Tracleer — pulmonary-hypertension medicines that came in with the 2017 acquisition of Actelion.
• Caplyta — a neuroscience drug J&J added by acquiring Intra-Cellular Therapies in 2025.

Two of those entries are worth dwelling on because they show the acquisition machinery in action. When J&J bought Actelion in 2017, the deal ran through a Swiss subsidiary, and the acquired pulmonary-hypertension franchise was folded into the existing pharmaceutical structure rather than bolted onto the parent. Notably, Actelion's early-stage drug discovery operations were spun out at the same time into a separate Swiss company called Idorsia, which is independent and never became part of J&J — a detail that catches people who assume an acquisition swallows everything a target once held. When J&J acquired Intra-Cellular Therapies in 2025, an all-cash merger brought the neuroscience drug Caplyta into the fold.

The structural point underneath those deals matters more than the drug names. Acquisitions of this scale are routinely executed through Delaware merger subsidiaries — a shell entity is formed, it merges with the target, and the target survives as a wholly owned subsidiary. That is the same kind of entity, structurally, that a founder forms on day one: a Delaware company created for a specific purpose. The multinational simply runs the maneuver constantly and at enormous scale. When you form your own Delaware LLC, you are reaching for the same toolbox, using one tool from it instead of dozens. It is also worth stressing that the names above are drug brands rather than separate companies you could buy shares in; the operating company that owns them is Johnson & Johnson Innovative Medicine, sitting within the wider J&J group.

What does Johnson & Johnson MedTech own?

MedTech is the medical-device half of the company, and unlike the drug side its assets are recognizable operating brands. After J&J consolidated its device businesses under the MedTech identity, the following sit inside the segment and are genuinely owned by J&J:

• Ethicon — surgical instruments, sutures, and wound closure.
• DePuy Synthes — orthopaedics, including joint reconstruction and trauma.
• Biosense Webster — heart-rhythm (electrophysiology) technology.
• Abiomed — heart-recovery and circulatory-support devices, acquired in 2022.
• Shockwave Medical — intravascular lithotripsy for artery disease, acquired in 2024.
• Cerenovus — stroke and neurovascular care.
• Johnson & Johnson Vision — the maker of Acuvue contact lenses.

Several of those MedTech names arrived by acquisition rather than internal development, which underscores the same theme running through the drug side. Abiomed, the heart-recovery business, was acquired in 2022. Shockwave Medical, which makes an intravascular lithotripsy platform for treating calcified artery disease, was acquired in 2024. Each came in as its own company and now operates as a brand inside the segment. The cardiovascular cluster in particular — Biosense Webster, Abiomed, Shockwave, and the neurovascular work at Cerenovus — reflects a deliberate build-out of one of the largest and fastest-growing areas of the device market, assembled piece by piece through deals that each ran through their own corporate mechanics.

MedTech is also where J&J's next planned separation lives. In late 2025 the company said it intends to spin off its orthopaedics business — which operates as DePuy Synthes — into a standalone company over roughly the next 18 to 24 months. As with any corporate separation, that timeline is a stated plan and could shift, so it is worth confirming the current status rather than treating it as settled fact. If it proceeds, it would echo the Kenvue playbook of carving out a self-contained business and letting it stand on its own — and it is a reminder that ownership lists for a company this active have a shelf life. The brands a giant owns this quarter are not guaranteed to be the brands it owns next year, which is exactly why hedging acquisition and spin-off dates is the responsible way to write about them.

Which brands are commonly mistaken as owned by J&J but are NOT?

This is where most ownership lists go wrong, so it deserves its own section. The brands below are frequently attributed to Johnson & Johnson and are not part of J&J today.

A further wrinkle: Kenvue itself is on track to change hands. In November 2025, Kimberly-Clark announced an agreement to acquire Kenvue, a transaction expected to close around the second half of 2026. That means Tylenol and the other consumer brands are not only outside J&J — they may soon sit under a different corporate parent entirely. The safe rule when listing what J&J owns is to exclude anything in the consumer-health category.

Why do giant companies hold their businesses through Delaware entities?

The reason a multinational layers Delaware subsidiaries under its parent is not glamour — it is predictability. Delaware has the most developed body of corporate case law in the United States and a dedicated business court, the Court of Chancery, that hears corporate disputes without juries and produces detailed, citable rulings. When a company is constantly raising money, signing major contracts, and acquiring other businesses, that legal certainty reduces risk at every step.

A second reason is structural cleanliness. A holding company can sit above a set of operating entities, each a separate Delaware filing, so that the liabilities of one business do not automatically reach the assets of another. When a group buys a company, it can drop the acquired business into a new or existing Delaware subsidiary instead of merging it messily into the parent. This is the everyday plumbing of corporate America, and Delaware is where most of that plumbing is installed.

A third reason is acquisition mechanics. Because Delaware merger law is so well understood, lawyers on both sides of a deal can model exactly how a transaction will work before signing. When J&J absorbed Actelion, Abiomed, Shockwave, and Intra-Cellular Therapies, each deal needed an entity to merge with the target and a clean way to hold the result. Delaware subsidiaries make that routine. The same predictability that helps a multinational close a $14-billion acquisition also helps a small company take on an investor, add a co-founder, or sell the business later, because the rules everyone is operating under are settled and tested.

The encouraging part for a small founder is that none of this requires scale. The same statute — the Delaware Limited Liability Company Act — the same Division of Corporations, and the same Court of Chancery stand behind a one-member Delaware LLC as behind a Fortune 50 subsidiary. You are not getting a watered-down version of Delaware; you are using the identical jurisdiction, sized to your needs. That is the quiet equalizer of the US corporate system: the legal home that a global healthcare empire chooses for its operating companies is open, on the same terms, to someone forming their very first business from a laptop on the other side of the world.

How does a single founder use the same Delaware vehicle J&J uses?

You do not need a holding company, a board, or a stack of entities. For almost every founder, the right starting structure is one Delaware LLC. It gives you a recognized US legal identity, a wall between your business and your personal assets, and a clean base from which to open banking and accept payments. The formation route is the same Delaware LLC formation path, adapted so it works even if you have no US Social Security Number, visa, or address.

In practice the sequence is short. You confirm an available name, we file the Certificate of Formation with a Delaware registered agent included, and your LLC legally exists in about 48 hours. From there you apply for an EIN for your Delaware LLC, which takes 2 to 4 weeks for applicants without an SSN, and then you move on to banking and payments. The full walkthrough lives on our how it works page.

The contrast with J&J is the point. A multinational runs hundreds of entities because it operates hundreds of distinct businesses across the world. You run one because you have one. Same state, same legal framework, vastly simpler footprint — and a setup you can complete remotely from anywhere. There is no requirement to ever graduate into a holding-company structure; most founders run a single LLC for the life of the business and never need a second entity. The layered-subsidiary model J&J uses is a response to complexity that a one-business founder simply does not have, and adding entities you do not need just multiplies filings and annual fees for no benefit.

Once your LLC is formed and the EIN is issued, the practical next step is US banking. You can open a US business bank account in the company's name even as a non-resident: fintech banks such as Mercury, Relay, and Wise onboard founders entirely online, and approval typically lands within 1 to 5 business days after the EIN is in hand. Approval is always the bank's own decision, never ours, so we help you present a clean application and apply to more than one provider if the first does not work out. Our Delaware LLC banking guide walks through the options in detail.

If you sell online, you will likely also want Stripeto accept card payments. Stripe approval is the provider's decision and is not guaranteed either; a clear business description and consistent details across your formation documents, EIN letter, and application are what help a review go smoothly. We do not promise approval from any bank or processor and we never quote an approval percentage — what we commit to is helping you apply correctly and trying alternatives if a first application is declined, because each provider reviews independently and a decline from one is not a decline from all. That honesty is deliberate: the giants get banking by relationship and scale, while a new founder earns it by presenting a clean, consistent file.

What does this cost, in year one and year two?

Our service is a single flat fee of $397, and the Delaware state filing fee is already included — there is no separate state charge bolted on at checkout. That covers the Certificate of Formation, the EIN application, a registered agent for year one, your operating agreement, and US bank and Stripe application support. The table below lays out the recurring picture so there are no surprises in year two.

The one ongoing state obligation for a Delaware LLC is the flat $300 franchise tax, due June 1 starting the year after you form. There is no annual report for an LLC. Miss the June 1 deadline and Delaware adds a $200 penalty plus 1.5% interest per month, and the LLC loses good standing — which is exactly why we track the date for you. The full breakdown is on our Delaware LLC cost page and our Delaware franchise tax guide.

It is worth clearing up one of the most common points of confusion here, because it directly involves the difference between you and a company like J&J. Delaware calculates corporate franchise tax using two methods — the authorized shares method and the assumed par value capital method — and those calculations can produce very large bills. They apply only to Delaware corporations, the kind of entity J&J's subsidiaries frequently are. They do not apply to LLCs at all. A Delaware LLC pays a single flat amount: $300 per year, full stop, with no share-based math and no annual report to file. So while a giant like J&J keeps tax teams busy working through corporate franchise-tax methods across many entities, your single LLC faces one predictable number each June.

If you ever did want a corporation instead — for example to raise venture capital from US investors who expect a C-Corp — the structure and its heavier compliance, including the corporate franchise-tax methods and an annual report, are covered on our Delaware C-Corp page. For the wider federal and state tax picture of running an LLC, including how a single-member LLC is treated as a pass-through by default, see our Delaware LLC taxes overview. Whether a non-resident owner ultimately owes US income tax is a fact-specific question that turns on the nature of the business and any applicable tax treaty, so it is best confirmed with a qualified CPA rather than assumed from a general rule.

What do non-resident founders need to know to copy this structure?

You can form and own a Delaware LLC from outside the United States with no US Social Security Number, no ITIN, no visa, and no US address. That is the whole premise of our service, and it is laid out in full on our Delaware LLC for non-residents guide. The EIN is obtained with Form SS-4, which the IRS processes by fax or mail for non-resident applicants — the reason it takes 2 to 4 weeks rather than minutes.

The one federal filing most non-resident single-member owners must not miss is Form 5472. If a non-US person owns 25% or more of a single-member Delaware LLC treated as a disregarded entity, the IRS requires Form 5472 each year, attached to a pro forma Form 1120, reporting transactions between you and your LLC. The penalty for failing to file is $25,000 under IRC 6038A, and the return is due April 15 (extendable with Form 7004). We track this for the founders we work with; the detail is in our Form 5472 for Delaware LLCs guide.

On beneficial-ownership reporting, the rules changed meaningfully in 2025, and it is worth being careful about how you describe them. A FinCEN interim final rule issued in March 2025 removed the BOI reporting obligation for US-formed domestic reporting companies, leaving only certain foreign reporting companies registered to do business in the US within scope. That is a significant shift from the framework many older guides describe, and the area is still evolving. The responsible approach is to confirm the current FinCEN position at the source before relying on any summary, rather than treating previously published deadlines as if they remain in force. We flag changes to founders we work with, but the duty to file if a filing is ever required rests with the owner.

How does forming one LLC compare to the alternatives?

A single Delaware LLC is the right starting point for most founders, but it is worth seeing it next to the other paths. The comparison below is a quick orientation, not legal advice — confirm the right structure with an advisor before deciding.

Notice that the holding-company row is the J&J pattern in miniature: it makes sense precisely when you have many separate businesses to keep apart, each with its own liabilities, contracts, and possible buyers. That is the situation a multinational lives in every day, and it is why Delaware subsidiaries stacked under a parent are worth the overhead for them. For a founder with one business, that same machinery is pure unnecessary cost — more filings, more annual franchise taxes, more bookkeeping, and no added protection you would actually use. The lesson to draw from studying what J&J owns is not to imitate its complexity but to recognize that the building block underneath all of it is a single Delaware entity, and that one building block is all most founders need.

So start with one Delaware LLC. It gives you the recognized US identity, the liability separation, and the clean banking base that the giants get from their Delaware subsidiaries, without the apparatus they carry to manage hundreds of them. If your plans later call for outside investment, our Delaware C-Corp guide explains when the corporate route earns its extra weight, and our how it workspage shows the full path from name check to a funded account. Either way, you can begin the whole process remotely, today, from anywhere in the world — the same Delaware framework J&J's subsidiaries rely on, available to you for a flat $397 with the state filing fee included.

Many of these companies chose Delaware for the same reasons founders do today — the Court of Chancery, flexible LLC statutes, and strong privacy protections. Form your Delaware LLC for $397, all-inclusive, in 48 hours. Form your Delaware LLC → | Read the complete Delaware LLC guide →